Matthew Labriola

<i>LRP1B</i> mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types

Landon C. Brown, Matthew D. Tucker, Ramy Sedhom et al. · Journal for ImmunoTherapy of Cancer · 2021 · 109 citations · Full text

Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients

Sarabjot Pabla, Jeffrey M. Conroy, Mary Nesline et al. · Journal for ImmunoTherapy of Cancer · 2019 · 106 citations · Full text

Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma

Matthew Labriola, Jason Zhu, Rajan T. Gupta et al. · Journal for ImmunoTherapy of Cancer · 2020 · 98 citations · Full text

Immunology, Immunoediting, Pathology +16

Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors

Jeffrey M. Conroy, Sarabjot Pabla, Mary Nesline et al. · Journal for ImmunoTherapy of Cancer · 2019 · 87 citations · Full text

Proliferative potential and response to nivolumab in clear cell renal cell carcinoma patients

Tian Zhang, Sarabjot Pabla, Felicia L. Lenzo et al. · OncoImmunology · 2020 · 28 citations · Full text